Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Prevention of Cystic Fibrosis Diabetes
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 33
- Registration Number
- NCT00967798
- Locations
- 🇺🇸
Emory University and Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States
🇺🇸Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Effect of Sitagliptin in Impaired Glucose Tolerance
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2010-03-22
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00961363
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT00960453
- Locations
- 🇰🇷
Clinical Trials Center; Seoul National University Hospital, Seoul, Korea, Republic of
Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Phenomix
- Target Recruit Count
- 360
- Registration Number
- NCT00958269
- Locations
- 🇺🇸
Phenomix Investigational Site 107, Columbia, South Carolina, United States
🇺🇸Phenomix Investigational Site 116, Pembroke Pines, Florida, United States
🇷🇺Phenomix Investigational Site 203, Moscow, Russian Federation
Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2010-11-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 400
- Registration Number
- NCT00957060
- Locations
- 🇲🇽
Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico
Effect of Sitagliptin on Postprandial Lipoprotein Metabolism
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 3
- Registration Number
- NCT00939939
- Locations
- 🇩🇪
Medical Dept. 2, Grosshadern, University Munich, Munich, Germany
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 3
- Registration Number
- NCT00936663
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 693
- Registration Number
- NCT00901979
- Locations
- 🇺🇸
Metabolic Research Institute, Inc., West Palm Beach, Florida, United States
🇺🇸John Muir Clinical Research, Concord, California, United States
🇺🇸Dallas Diabetic and Endocrinology Research Center, Dallas, Texas, United States
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00888238
Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Lund University
- Target Recruit Count
- 12
- Registration Number
- NCT00885638
- Locations
- 🇸🇪
Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.